

About the author

Disclaimer

EXECUTIVE SUMMARY

An introduction to drug delivery partnerships

The drug delivery value chain

Partnering trends in drug delivery technology

Drug delivery partnerships for lifecycle management

Drug delivery partnerships for novel drug delivery applications

Drug delivery partnerships for complex development compounds

Best practices for effective drug delivery partnering

An introduction to drug delivery partnerships

Summary

Introduction

Report objectives

Report methodology

Report structure

The drug delivery value chain

Summary

Introduction

Drug delivery technologies in context

Oral drug delivery

Topical/transdermal drug delivery

Transmucosal drug delivery

Inhalation drug delivery

Injection drug delivery

Other novel drug delivery technologies

Platform versus applied technologies

Drug delivery development

Drug delivery productivity

Branded drug delivery products

Generic drug delivery products

In-house versus external technology development

The drug delivery partnership model

Drug delivery partnerships for lifecycle management

Drug delivery partnerships for novel drug delivery applications

Drug delivery partnerships for complex development compounds

Partnering trends in drug delivery technology

Summary

Introduction

Global partnering trends

Product versus technology

Partnering trends by level of collaboration

Trends by partners

Partnering trends in context

Future partnering trends

Drug delivery partnerships for lifecycle management

Summary

Introduction

Market expansion and generic defense strategies

Case study: Suboxone sublingual film line extension

Case study: Vyteris repositions as a contract research organization

Case study: Mylan acquires dry-powder delivery technology from Pfizer

Key challenges and critical success factors

Timing versus flexibility

Proof of concept versus risk management

Collaboration versus assigned responsibilities

Additional expert insights

Drug delivery partnerships for novel drug delivery applications

Summary

Introduction

Competitive market differentiation strategies

Case study: Intermezzo delivers new indication

Case study: Flutiform partner runs out of patience

Case study: Alkermes acquires a new position in drug delivery space

Key challenges and critical success factors

Partner funding versus partner expertise

Focused application versus consolidated portfolio

Common objectives versus competitive repositioning

Additional expert insights

Drug delivery partnerships for complex development compounds

Summary

Introduction

Innovative drug development strategies

Case study: Vectura's partnering-based evolution down-stream

Case study: Alkermes delivers game changing value in tripartite development partnership

Case study: ThermoDox's drug delivery device, clinical and commercial partnering network

Key challenges and critical success factors

Technology value versus partnering rewards

Commercial validation versus evolving down-stream

Partner of choice versus complementary partner objectives

Additional expert insights

Best practices for effective drug delivery partnering

Summary
Introduction
Maximizing therapeutic value
Delivering effective differentiation
Enabling complex development programs
Strategic partnering

Appendix

Methodology
 Primary research
Glossary/Abbreviations
Bibliography/References

TABLES

Table: Drug delivery development and approval
Table: Branded drug delivery product prescriptions in US, 2009–10
Table: Leading branded drug delivery products by US sales, 2010
Table: Generic drug delivery product prescriptions in US, 2009–10
Table: Key drug delivery partnership deals, 2000–11

FIGURES

Figure: Drug delivery product approvals in US, 2001–10
Figure: US branded drug delivery product sales in top 200 products, 2009–10
Figure: US branded drug delivery product cost/prescription, 2009–10
Figure: Leading branded drug delivery products by US sales, 2010
Figure: US generic drug delivery product sales in top 200 products, 2009–10
Figure: Generic drug delivery product cost/prescription in US, 2009–10
Figure: Leading generic drug delivery products by US sales, 2010
Figure: Drug delivery partnerships for lifecycle management
Figure: Drug delivery partnerships for novel drug delivery applications
Figure: Drug delivery partnerships for complex development compounds
Figure: Drug delivery partnership deals, 2000–10
Figure: Product versus technology-based drug delivery deals, 2000–10
Figure: Product versus technology-based drug delivery deal values, 2000–10
Figure: Leading drug delivery partnership technologies, 2001–10
Figure: Drug delivery partnerships by degree of collaboration, 2000–10
Figure: Drug delivery partnership values by degree of collaboration, 2000–10
Figure: Drug delivery partnerships by partner, 2000–10
Figure: Drug delivery partnership values by partner, 2000–10
Figure: Top 10 pharma companies by number of drug delivery deals, 2000–H1 2011
Figure: Leading drug delivery partners by number of deals, 2000–H1 2011